DE69430416T2 - Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen - Google Patents

Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen

Info

Publication number
DE69430416T2
DE69430416T2 DE69430416T DE69430416T DE69430416T2 DE 69430416 T2 DE69430416 T2 DE 69430416T2 DE 69430416 T DE69430416 T DE 69430416T DE 69430416 T DE69430416 T DE 69430416T DE 69430416 T2 DE69430416 T2 DE 69430416T2
Authority
DE
Germany
Prior art keywords
cysteine
amino acid
proportion
infections
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430416T
Other languages
English (en)
Other versions
DE69430416D1 (de
DE69430416T3 (de
Inventor
Maurice Arnal
Francis Rose
Denis Breuille
Christiane Obled
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Institut National de la Recherche Agronomique INRA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9452315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69430416(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe des Produits Nestle SA, Nestle SA, Institut National de la Recherche Agronomique INRA filed Critical Societe des Produits Nestle SA
Publication of DE69430416D1 publication Critical patent/DE69430416D1/de
Application granted granted Critical
Publication of DE69430416T2 publication Critical patent/DE69430416T2/de
Publication of DE69430416T3 publication Critical patent/DE69430416T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE69430416T 1993-10-28 1994-10-27 Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen Expired - Lifetime DE69430416T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9312884A FR2711529B1 (fr) 1993-10-28 1993-10-28 Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
FR9312884 1993-10-28

Publications (3)

Publication Number Publication Date
DE69430416D1 DE69430416D1 (de) 2002-05-23
DE69430416T2 true DE69430416T2 (de) 2002-12-05
DE69430416T3 DE69430416T3 (de) 2009-01-22

Family

ID=9452315

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430416T Expired - Lifetime DE69430416T3 (de) 1993-10-28 1994-10-27 Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen

Country Status (9)

Country Link
EP (1) EP0655244B2 (de)
KR (1) KR950010884A (de)
AT (1) ATE216234T1 (de)
CA (1) CA2134380C (de)
DE (1) DE69430416T3 (de)
DK (1) DK0655244T5 (de)
ES (1) ES2171439T5 (de)
FR (1) FR2711529B1 (de)
PT (1) PT655244E (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038507A1 (en) * 1998-01-30 1999-08-05 David George Le Couteur Reversal and prevention of clinically significant aspects of aging through oral use of hepatic artery vasodilator and other agents which increase hepatic oxygenation
WO2001056405A2 (en) * 2000-02-04 2001-08-09 Societe Des Produits Nestle S.A. A method for maintaining or improving the synthesis of mucins
EP1302115A1 (de) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Verwendung von Cystathionin
JP2007522208A (ja) * 2004-02-12 2007-08-09 キャンピナ・ネダーランド・ホールディング・ビー．ブイ． チオールのホメオスタシスを改良するためのシステインリッチのペプチド
US20090209647A1 (en) * 2005-06-14 2009-08-20 Nestec S.A. Nutritional method
EP2165713B1 (de) 2008-09-19 2012-11-14 Nestec S.A. Molke und Verbesserung der Thymusfunktion
WO2011021926A1 (en) 2009-08-21 2011-02-24 N.V. Nutricia Regulating the amino acid pool used for the acute-phase protein synthesis
EP2444083A1 (de) 2010-10-21 2012-04-25 Nestec S.A. Cystein- und Nahrungsmittelaufnahme

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2531204A1 (de) * 1975-07-12 1977-01-13 Fresenius Chem Pharm Ind L-aminosaeuregemische fuer parenterale oder orale anwendung
DE2946563A1 (de) * 1979-11-17 1981-05-21 B. Braun Melsungen Ag, 3508 Melsungen Aminosaeureloesung zur parenteralen infusion
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US4604286A (en) * 1984-09-17 1986-08-05 Daigo Nutritive Chemicals, Ltd. Infusion solution for parenteral nutrition
ES2039402T3 (es) * 1986-10-24 1993-10-01 Pfrimmer Kabi Gmbh & Co. Kg Empleo de peptidos n,n'-bis-l-aminoacido-l-cistina en preparados de aminoacidos para alimentacion oral y parenteral.
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
US5224409A (en) † 1991-03-19 1993-07-06 Ashlock Company Apparatus for producing helical slices
US5214062A (en) † 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
AU6060694A (en) † 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung

Also Published As

Publication number Publication date
CA2134380C (en) 2010-06-22
FR2711529A1 (fr) 1995-05-05
EP0655244B1 (de) 2002-04-17
ES2171439T5 (es) 2008-12-01
EP0655244B2 (de) 2008-06-11
ATE216234T1 (de) 2002-05-15
DE69430416D1 (de) 2002-05-23
EP0655244A1 (de) 1995-05-31
FR2711529B1 (fr) 1996-07-05
KR950010884A (ko) 1995-05-15
DK0655244T5 (da) 2008-10-13
DK0655244T3 (da) 2002-08-05
CA2134380A1 (en) 1995-04-29
ES2171439T3 (es) 2002-09-16
PT655244E (pt) 2002-08-30
DE69430416T3 (de) 2009-01-22

Similar Documents

Publication Publication Date Title
DE69305105T2 (de) Zusammensetzungen zur oralen Nahrungsmittelaufnahme mit verbessertem Geschmack
DE69429297T2 (de) Zusammensetzung zur Behandlung von Patienten mit Lebererkrankungen
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
ATE165100T1 (de) Peptide mit endothelin antagonistischer aktivität, deren herstellung und pharmazeutische zusammensetzungen
ES2141229T3 (es) Productos farmaceuticos de proteinas y peptidos modificados.
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
DE59810596D1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
DE69430416D1 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
DE3866045D1 (de) Arzneimittel zur behandlung von uraemie.
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
DE60104695D1 (de) Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE60001489T2 (de) Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
WO1998001474A3 (en) Derivatives of somatostatin, amino acids or oligopeptides and their combination useful for promoting body growth
DE60040856D1 (de) Lactalbumin zur kurativen Behandlung von Magengeschwüren
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: SOCIETE DES PRODUITS NESTLE S.A., VEVEY, CH

Owner name: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE , FR